Skip to main content

Table 3 FMF-50 response criteria

From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

Parameters

At least 50% reduction

Attack frequency

63/65 (96.9%)

Durations of attacks

63/65 (96.9%)

Patients VAS

64/65 (98.5%)

Physicians VAS

64/65 (98.5%)

CRP (at least 2 weeks after the last attack)

62/65 (95.3%)

Arthritis

9/11 (81.8%)

  1. Values presented by % frequency. VAS Visual Analogue Scale, CRP C reactive protein